Page 1

CANDEL THERAPEUTICS Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights November 12 , 2021 NEEDHAM , Mass . , Nov. 12 , 2021 ( GLOBE NEWSWIRE ) -- Candel Therapeutics , Inc. ( " Candel " or " the Company " ) ( Nasdaq : CADL ) , a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies , today reported financial results for the third quarter ended September 30 , 2021 and provided a corporate update . " With the completion of our IPO in August 2021 and multiple data readouts across our product candidates expected over the next 12 months , we are well - capitalized and in a strong position to advance on the Company's goal to bring novel oncolytic viral immunotherapies to patients with cancer , " said Paul Peter Tak , MD , PhD , FMedSci , President and Chief Executive Officer of Candel Therapeutics . " In the quarter and recent weeks , we expanded visibility of our technology and clinical programs with six presentations at medical conferences , highlighting clinical observations for our lead product candidate from our adenoviral platform , CAN - 2409 , in prostate cancer and our lead product candidate from our HSV platform , CAN - 3110 , in high - grade glioma , two areas of significant unmet need . " Third Quarter 2021 & Recent Highlights • In September , Scott E. Eggener , MD , principal investigator , presented data at the AdMeTech Foundation's Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer , highlighting safety observations from the Company's phase 2 clinical trial of CAN - 2409 in patients with localized , low to intermediate risk prostate cancer undergoing active surveillance . • Also in September , E. Antonio Chiocca , MD , PhD , FAANS , principal investigator , presented clinical and immunological biomarker data from the phase 1 clinical trial of CAN - 3110 in patients with recurrent high - grade glioma at the 16th Meeting of the European Association of Neuro - Oncology . • In October , Dr. Tak provided a technology overview at the Cambridge Healthtech Institute's 9th Annual Immuno - Oncology Summit in a session titled Novel Oncolytic Viral Immunotherapies for Solid Tumors . . Separately , at the Hanson Wade 6th Annual Oncolytic Virotherapy Summit held in October , Dr. Tak highlighted Candel's approach with its novel oncolytic viral immunotherapies , CAN - 2409 and CAN - 3110 , to immunize against a patient's own tumor neo - antigens . Also at this conference , Dr. Chiocca presented on the Company's CAN - 3110 program in glioblastoma . • In October , the Company announced the appointment of Mace L. Rothenberg , MD , as a senior advisor to Dr. Tak . Dr. Rothenberg , an industry veteran with more than 30 years of experience across government , academia and industry , will help support the Company's continued growth and acceleration . • Also in October , the Company's Chief Medical Officer , Laura K. Aguilar , MD , PhD , presented data on patient- reported tolerability of intraprostatic injections at the 28th Annual Prostate Cancer Foundation Scientific Retreat . These data further support patient receptiveness to intra - prostatic injection of CAN - 2409 and its comparability , in terms of tolerance , to routine intra - prostatic biopsies . • In early November , the Company had two presentations at the 13th International Oncolytic Virus Conference Meeting . Dr. Chiocca provided details on the first - in - human clinical trial of CAN - 3110 in glioblastoma . Dr. Tak gave a talk in a Special Session , titled Leveraging Viral Oncolytic Immunotherapy Platform to Tip the Balance in Favor of the Immune System that highlighted recent advancements of CAN - 2409 and CAN - 3110 development , including the enrollment completion and patient tolerability data from the phase 3 trial in prostate cancer , and the blinded safety data from the phase 2 clinical trial in patients with prostate cancer undergoing active surveillance . • Also in November , the Company's Vice President , Head of Research , Francesca Barone , MD , PhD , presented novel biomarker data from the ongoing phase 1 open - label , dose - escalation clinical trial of CAN - 3110 in patients with recurrent high - grade glioma at the Society for Immunotherapy of Cancer's ( SITC ) 36th Annual Meeting . The presentation focused on the biological findings of this study , showed the ability of CAN - 3110 to induce immune activation both locally , in the tumor microenvironment , and systemically in peripheral blood of treated patients . Key Upcoming Milestones • Patrick Y. Wen , MD , principal investigator , will present initial safety data on CAN - 2409 in combination with nivolumab from a phase 1 clinical trial in high - grade glioma at the 26th Annual Meeting of the Society for Neuro - Oncology ( SNO ) in